Gilead Sciences, Inc.

Jamie Geier Bates

Adrian S Ray

David Gordon Clarkson Breckenridge

John T Liles

James G Taylor

William John Watkins

Michael L Mitchell

Hongyan Guo

Ana Zurisadai Gonzalez Buenrostro

Xiaochun Han

Gregg M Schwarzwalder

Ting Wang

Brian J Kirby

Yurong Lai

David Gordon Breckenridge

The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.

Combination therapy comprising an ACC inhibitor

The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ACC inhibitor in combination with an FXR agonist to a patient in need thereof.

Methods of treating liver disease

The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Thienopyrimidine derivatives as ACC inhibitors and uses thereof

The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ASK1 inhibitor in combination with a FXR agonist, to a patient in need thereof.

Growing community of inventors

Burlingame, CA, United States of America

Jamie Geier Bates